ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

November 5, 2018

Leaders from the ASCO State Affiliate Council met to discuss pressing issues in oncology, including drug pricing, Medicaid work requirements, changes to the Medicare physician fee schedule, and the role of pharmacy benefit managers (PBMs).

November 2, 2018

The Centers for Medicare & Medicaid Services (CMS) released the final rule for the Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) outlining reimbursement changes for  2019. CMS estimates that the overall impact will be a one percent reimbursement cut for the hematology/oncology and radiation/oncology specialties in 2019. Based on feedback from ASCO, significant changes were made, which helped to avoid an overall four percent reduction for the specialty. However, it is important to note that the actual impact on individual physician practices will depend on the mix of services the practice provides.

November 2, 2018

The Centers for Medicare & Medicaid Services (CMS) released its 2019 Hospital Outpatient Prospective Payment System (HOPPS) final rule. An initial evaluation of the rule found that CMS finalized provisions cutting Medicare reimbursement for certain visits to hospital outpatient clinics and to extend 2018 cuts to the 340B Drug Pricing Program.  

November 1, 2018

On October 29 and 30, the initial sessions of the full six-month Quality Training Program are being held in Madrid, marking both the first time the program has been licensed outside of the U.S. and conducted in Spain. 

October 30, 2018

Nearly four in 10 Americans believe cancer can be cured solely through alternative therapies, according to the American Society of Clinical Oncology (ASCO)’s second annual National Cancer Opinion Survey. This is despite research showing that patients who use alternative therapies instead of standard cancer treatments have much higher mortality rates. The survey also found that amid the ongoing opioid crisis, nearly three in four Americans are opposed to limiting access to opioids for people with cancer, and many cancer patients report difficulty obtaining these medications. In addition, just as many Americans say they are worried about the financial impact of a cancer diagnosis as about dying of cancer, with caregivers and rural Americans bearing the weight of cancer’s financial and access challenges. The National Cancer Opinion Survey is a large, nationally representative survey conducted online by The Harris Poll.

October 30, 2018

On October 30, 2018, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck & Co. Inc.) in combination with carboplatin and either paclitaxel or nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).

October 26, 2018

On October 25, 2018, CMS released the International Pricing Index Model for Medicare Part B Drugs, an advanced notice of a proposed rule that, if implemented, would establish a pilot program to test ways to lower the costs of drugs. Provisions in the proposal include benchmarking some part B drug prices against other countries and changing how providers get paid for administering drugs to patients. The proposal marks the most sweeping changes the Administration has put forth to implement the President Trump’s “blueprint to lower drug prices and reduce out-of-pocket costs.”

October 24, 2018

ASCO recently submitted two comment letters from ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, to the Food and Drug Administration (FDA) Commissioner Scott Gottlieb related to the modernization of clinical trials.

October 24, 2018

This year we celebrate Healthcare Quality Week October 21–26, a time dedicated to celebrating the contributions professionals have made to improve health care quality. For 2018, ASCO is using this time to recognize practices—and the individuals on their oncology care teams—that have participated in offerings and expansions in several Society programs aimed at improving the quality of cancer care.

October 23, 2018

In the latest ASCO in Action Podcast, ASCO CEO Dr. Clifford A. Hudis highlights key studies from this year’s ASCO Quality Care Symposium, an annual meeting that brings together oncology leaders and members of the cancer care team to share strategies and methods for improving measurement and implementation of quality and safety activities in oncology. 

October 22, 2018

ASCO’s Policy Issue Briefs provide succinct overviews and relevant data on major policy issues impacting patients with cancer and the physicians who care for them. These briefs are designed to be especially helpful for journalists, offering background information on key issues across health policy today.

October 22, 2018

A bipartisan group of more than 100 members of the U.S. House of Representatives signed a letter to Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma urging the Agency to review and improve prior authorization practices under Medicare Advantage (MA). The letter, led by Rep. Ami Bera, MD (CA-7), and Rep. Phil Roe, MD (TN-1), cites concerns that MA beneficiaries may be encountering barriers to care due to “onerous and often unnecessary prior authorization requirements.”

October 19, 2018

ASCO and the Society for Immunotherapy of Cancer (SITC) have released a joint statement with twelve clinical trial reporting recommendations that address the unique efficacy, toxicity, and combination/sequencing aspects of immuno-oncology (IO) treatments. These recommendations, jointly published in the Journal of Clinical Oncology (JCO) and Journal for ImmunoTherapy of Cancer (JITC), will lead to better IO trial reporting and assessment.

October 18, 2018

Richard L. Schilsky, MD, FACP, FSCT, FASCO, Senior Vice President and Chief Medical Officer of ASCO will moderate a panel at an upcoming public meeting of the Reagan-Udall Foundation for the Food and Drug Administration (FDA) on November 19, 2018, at the FDA main campus at White Oak.

October 18, 2018

On October 17, the Journal of the National Cancer Institute published a manuscript summarizing the action items coming out of the joint ASCO/U.S. Food and Drug Administration Geriatric Oncology Workshop, held Nov. 6, 2017. 

Pages